HLA-C and cancer: The information of neo-antigens and specific peptides that can be presented by MHC molecule of an individual patient can be predicted from the mutated genes obtained from genomic or transcriptomic sequence of the patient’s cancer cells compared with that of normal cells or identified from whole peptide ligands (ligandome) binding to MHC molecules.